Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHS-006 and Toripalimab in Advanced Solid Tumors
NCT05757492Phase 1Terminated
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JS006 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) (4 arms), sponsored by Coherus BioSciences, Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Apr 2023; status: terminated.
02
Drugs
JS006
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05757492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757492.